Published in Acta Anaesthesiol Scand on September 01, 1997
Malignant hyperthermia. Orphanet J Rare Dis (2007) 2.56
Next-generation Sequencing of RYR1 and CACNA1S in Malignant Hyperthermia and Exertional Heat Illness. Anesthesiology (2015) 1.67
Identification and functional characterization of malignant hyperthermia mutation T1354S in the outer pore of the Cavalpha1S-subunit. Am J Physiol Cell Physiol (2010) 1.17
Functional and genetic characterization of clinical malignant hyperthermia crises: a multi-centre study. Orphanet J Rare Dis (2014) 1.00
Store-operated Ca2+ entry in malignant hyperthermia-susceptible human skeletal muscle. J Biol Chem (2010) 0.96
Functional analysis of RYR1 variants linked to malignant hyperthermia. Temperature (Austin) (2016) 0.92
Malignant hyperthermia: a review. Orphanet J Rare Dis (2015) 0.92
Halothane modulation of skeletal muscle ryanodine receptors: dependence on Ca2+, Mg2+, and ATP. Am J Physiol Cell Physiol (2008) 0.91
Malignant hyperthermia and the clinical significance of type-1 ryanodine receptor gene (RYR1) variants: proceedings of the 2013 MHAUS Scientific Conference. Can J Anaesth (2014) 0.85
Is there a link between exertional heat stroke and susceptibility to malignant hyperthermia? PLoS One (2015) 0.85
Effects of Mg(2+) and SR luminal Ca(2+) on caffeine-induced Ca(2+) release in skeletal muscle from humans susceptible to malignant hyperthermia. J Physiol (2002) 0.83
Clinical utility gene card for: malignant hyperthermia. Eur J Hum Genet (2011) 0.81
A truncation in the RYR1 gene associated with central core lesions in skeletal muscle fibres. J Med Genet (2007) 0.80
Malignant hyperthermia susceptibility diagnosed with a family-specific ryanodine receptor gene type 1 mutation. J Anesth (2008) 0.80
Exome analysis identifies Brody myopathy in a family diagnosed with malignant hyperthermia susceptibility. Mol Genet Genomic Med (2014) 0.77
Malignant hyperthermia. Korean J Anesthesiol (2012) 0.77
The ryanodine receptor agonist 4-chloro-3-ethylphenol blocks ORAI store-operated channels. Br J Pharmacol (2014) 0.77
Lactic acid restores skeletal muscle force in an in vitro fatigue model: are voltage-gated chloride channels involved? Am J Physiol Cell Physiol (2012) 0.75
Exertional rhabdomyolysis and heat stroke: Beware of volatile anesthetic sedation. World J Crit Care Med (2017) 0.75
Effects of theophylline on anesthetized malignant hyperthermia-susceptible pigs. J Biomed Biotechnol (2011) 0.75
Hypermetabolism in B-lymphocytes from malignant hyperthermia susceptible individuals. Sci Rep (2016) 0.75
Testing for MH susceptibility. Acta Anaesthesiol Scand (1997) 0.75
[Malignant hyperthermia]. Wien Klin Wochenschr (2003) 0.75
A family with discordance between malignant hyperthermia susceptibility and rippling muscle disease. J Anesth (2012) 0.75
Genome sequence, comparative analysis, and population genetics of the domestic horse. Science (2009) 4.41
The skeletal muscle chloride channel in dominant and recessive human myotonia. Science (1992) 4.28
Transient neurologic toxicity after hyperbaric subarachnoid anesthesia with 5% lidocaine. Anesth Analg (1993) 4.24
A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology (1994) 3.23
Dantrolene--a review of its pharmacology, therapeutic use and new developments. Anaesthesia (2004) 2.50
Neuroleptic malignant syndrome. Br J Anaesth (2000) 2.48
Membrane changes in cells from myotonia patients. Physiol Rev (1985) 2.38
Study of a single BRCA2 mutation with high carrier frequency in a small population. Am J Hum Genet (1997) 2.28
Superhelicity-driven homologous DNA pairing by yeast recombination factors Rad51 and Rad54. Mol Cell (2000) 2.28
Acute heart failure during spinal surgery in a boy with Duchenne muscular dystrophy. Br J Anaesth (2003) 2.23
A calcium channel mutation causing hypokalemic periodic paralysis. Hum Mol Genet (1994) 2.22
Pharmacological prevention of sevoflurane- and desflurane-related emergence agitation in children: a meta-analysis of published studies. Br J Anaesth (2010) 2.17
The implementation of a perioperative checklist increases patients' perioperative safety and staff satisfaction. Acta Anaesthesiol Scand (2011) 2.15
Creatine therapy in myophosphorylase deficiency (McArdle disease): a placebo-controlled crossover trial. Arch Neurol (2000) 2.12
A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology (2011) 2.09
Halothane-induced muscle contracture as a cause of hyperpyrexia. Br J Anaesth (1971) 2.06
[Quality management in acute pain therapy: results from a survey of certified hospitals]. Schmerz (2012) 2.03
The nutritional status of vegans and vegetarians. Proc Nutr Soc (1967) 2.03
Management of lethal catatonia with dantrolene sodium. Crit Care Med (1991) 2.01
Cerebral microbleeds in the population based AGES-Reykjavik study: prevalence and location. J Neurol Neurosurg Psychiatry (2008) 1.99
Voltage-sensor sodium channel mutations cause hypokalemic periodic paralysis type 2 by enhanced inactivation and reduced current. Proc Natl Acad Sci U S A (2000) 1.97
Adynamia episodica hereditaria with myotonia: a non-inactivating sodium current and the effect of extracellular pH. Muscle Nerve (1987) 1.94
Peripheral nerve hyperexcitability due to dominant-negative KCNQ2 mutations. Neurology (2007) 1.90
Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet (1997) 1.88
Genotype-phenotype correlations in human skeletal muscle sodium channel diseases. Arch Neurol (1993) 1.88
[Generation Y : recruitment, retention and development]. Anaesthesist (2011) 1.86
Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2. Neurology (2010) 1.84
Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A. Brain (2001) 1.82
Screening for Duchenne muscular dystrophy: an improved screening test for creatine kinase and its application in an infant screening program. Muscle Nerve (1986) 1.79
Evidence for related myopathies in exertional heat stroke and malignant hyperthermia. Lancet (1991) 1.77
Malignant hyperthermia mutation Arg615Cys in the porcine ryanodine receptor alters voltage dependence of Ca2+ release. J Physiol (2000) 1.76
A mutation in the transmembrane/luminal domain of the ryanodine receptor is associated with abnormal Ca2+ release channel function and severe central core disease. Proc Natl Acad Sci U S A (1999) 1.74
Malignant hyperpyrexia myopathy. Q J Med (1973) 1.73
Sympatric bromeliad species (Pitcairnia spp.) facilitate tests of mechanisms involved in species cohesion and reproductive isolation in Neotropical inselbergs. Mol Ecol (2011) 1.72
Lumbovertebral syndrome after extradural blood patch. Br J Anaesth (1992) 1.71
A survey of the use of vitamin B12 in general practice. Practitioner (1970) 1.70
Evaluation of spin resonance spectroscopy of red blood cell membranes to detect malignant hyperthermia susceptibility. Br J Anaesth (1992) 1.69
Effects of ondansetron in the prevention of postoperative nausea and vomiting in children. Anesthesiology (1994) 1.65
Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J Med Genet (2008) 1.59
Identification of heterozygous and homozygous individuals with the novel RYR1 mutation Cys35Arg in a large kindred. Anesthesiology (1997) 1.58
Perlecan, the major proteoglycan of basement membranes, is altered in patients with Schwartz-Jampel syndrome (chondrodystrophic myotonia). Nat Genet (2000) 1.58
Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature (1990) 1.57
Myotonia fluctuans. Arch Neurol (1990) 1.56
In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects. Arthritis Rheum (2006) 1.55
K(+)-aggravated myotonia: destabilization of the inactivated state of the human muscle Na+ channel by the V1589M mutation. J Physiol (1994) 1.54
Estimation of the correct length of tracheal tubes in adults. Anaesthesia (1993) 1.53
Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve (2000) 1.50
Masseteric muscle spasm as a normal response to suxamethonium. Br J Anaesth (1990) 1.49
Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol (1995) 1.47
31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies. Neurology (1992) 1.47
Evolution of reproductive isolation in plants. Heredity (Edinb) (2008) 1.47
[New type of recessive X-linked muscular dystrophy: scapulo-humeral-distal muscular dystrophy with early contractures and cardiac arrhythmias]. Humangenetik (1972) 1.45
Hypokalemic periodic paralysis: in vitro investigation of muscle fiber membrane parameters. Muscle Nerve (1984) 1.44
Long-term effects of a perioperative safety checklist from the viewpoint of personnel. Acta Anaesthesiol Scand (2012) 1.44
[Parkinson's disease. Perioperative management and anesthesia]. Anaesthesist (2012) 1.44
Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia. Acta Anaesthesiol Scand (2004) 1.43
Phenotypic variability in rippling muscle disease. Neurology (1999) 1.43
Perioperative severe rhabdomyolysis revealing susceptibility to malignant hyperthermia. Anesthesiology (1998) 1.43
Hepatitis B e antigen, DNA polymerase activity, and infection of household contacts with hepatitis B virus. Gastroenterology (1979) 1.42
[Pros and cons of adding an accessory breathing system to the main circle circuit. II. Arguments against their use]. Ann Fr Anesth Reanim (1998) 1.40
Veganism, clinical findings and investigations. Am J Clin Nutr (1970) 1.40
Phylogeny and evolution of Orchis and allied genera based on ITS DNA variation: morphological gaps and molecular continuity. Mol Phylogenet Evol (1999) 1.39
An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor. Hum Mol Genet (2000) 1.39
Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia Group. Br J Anaesth (2010) 1.39
Two cases of adynamia episodica hereditaria: in vitro investigation of muscle cell membrane and contraction parameters. Muscle Nerve (1983) 1.39
Postoperative decrease in plasma sodium concentration after infusion of hypotonic intravenous solutions in neonatal surgery. Br J Anaesth (2013) 1.39
[Opioid-sparing effect of ketamine during tonsillectomy in children]. Ann Fr Anesth Reanim (2013) 1.39
[Retrograde percutaneous catheterization of the internal jugular vein in head injured patients]. Ann Fr Anesth Reanim (1995) 1.39
[Accidental spinal anesthesia in obstetrics. Limits of epidural test-dose]. Ann Fr Anesth Reanim (1992) 1.39
Protein concentration in pulmonary oedema fluid for negative pressure pulmonary oedema in children. Paediatr Anaesth (2000) 1.39
[Anesthetic technics for the difficult intubation]. Ann Fr Anesth Reanim (1990) 1.39
[What significance to genotype changes have in diagnosis of malignant hyperthermia?]. Anasthesiol Intensivmed Notfallmed Schmerzther (1996) 1.39
[Accessory anesthetic breathing systems: verification before use]. Ann Fr Anesth Reanim (1999) 1.38
Acute poisoning with amphetamines (MDEA) and heroin: antagonistic effects between the two drugs. Intensive Care Med (1996) 1.38
Evaluation of the Augustine Guide for difficult tracheal intubation. Can J Anaesth (1995) 1.38
Laryngospasm during transtracheal high frequency jet ventilation. Anaesthesia (1992) 1.37
Different effects on gating of three myotonia-causing mutations in the inactivation gate of the human muscle sodium channel. J Physiol (1995) 1.36
Is the "K-type" caffeine-halothane responder susceptible to malignant hyperthermia? Br J Anaesth (1992) 1.36
Myotonia fluctuans. A third type of muscle sodium channel disease. Arch Neurol (1994) 1.33
Hand osteoarthritis in older women is associated with carotid and coronary atherosclerosis: the AGES Reykjavik study. Ann Rheum Dis (2008) 1.33
Localization of the gene encoding the alpha 2/delta-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum Mol Genet (1994) 1.32
Ion channels and epilepsy. Am J Med Genet (2001) 1.32
Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology (1994) 1.31
Chlorocresol: an activator of ryanodine receptor-mediated Ca2+ release. Mol Pharmacol (1993) 1.31
4-Chloro-m-cresol, a potent and specific activator of the skeletal muscle ryanodine receptor. Biochim Biophys Acta (1996) 1.29
Regulation of the purified Ca2+ release channel/ryanodine receptor complex of skeletal muscle sarcoplasmic reticulum by luminal calcium. Pflugers Arch (1996) 1.29
Cerebral microbleeds, retinopathy, and dementia: the AGES-Reykjavik Study. Neurology (2010) 1.29
Adult behavioral and pharmacological dysfunctions following disruption of the fetal brain balance between pro-inflammatory and IL-10-mediated anti-inflammatory signaling. Mol Psychiatry (2007) 1.29
Paramyotonia congenita: the R1448P Na+ channel mutation in adult human skeletal muscle. Ann Neurol (1996) 1.28
Superoxide-dependent nitroblue tetrazolium reduction and expression of cytochrome b-245 components by human tonsillar B lymphocytes and B cell lines. J Immunol (1989) 1.27
Screening for malignant hyperpyrexia. Br Med J (1972) 1.27
A novel SCN4A mutation causing myotonia aggravated by cold and potassium. Hum Mol Genet (1993) 1.26
Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor 1: association with central core disease and alteration of calcium homeostasis. Hum Mol Genet (2001) 1.25